INTRODUCTION

**Review question / Objective:** To systematically examine the efficacy and safety of antidepressants added to treatment as usual (TAU) for patients suffering from COVID-19.

**Condition being studied:** Preliminary evidence showed that certain antidepressants appear to have potential as safe, inexpensive, and widely available medications that could improve COVID-19-related outcomes such as mortality. Therefore, this systematic review will examine the efficacy and safety of antidepressants added to treatment as usual (TAU) for patients suffering from COVID-19.

INPLASY registration number: This protocol was registered with the International Platform of Registered Systematic Review and Meta-Analysis Protocols (INPLASY) on 07 January 2022 and was last updated on 07 January 2022 (registration number INPLASY202210030).
antidepressants added to treatment as usual (TAU) for patients suffering from COVID-19.

METHODS

Search strategy: Chinese Journal Net, WanFang, PsycINFO, Cochrane Library, PubMed, and EMBASE databases will be independently searched by two authors for studies on adjunctive antidepressants for COVID-19, from their inceptions until December 9, 2021 using the following search terms: (Coronavirus OR COVID-19 OR SARS-CoV-2 OR 2019-nCoV OR coronavirus disease 2019) AND (agomelatine OR amitriptyline OR bupropion OR citalopram OR clomipramine OR desvenlafaxine OR duloxetine OR escitalopram OR fluoxetine OR fluvoxamine OR levomilnacpran OR milnacipran OR mirtazapine OR nefazodone OR paroxetine OR reboxetine OR sertraline OR trazodone OR venlafaxine OR vilazodone OR vortioxetin OR antidepressive agents).

Participant or population: Patients suffering from COVID-19.

Intervention: Treatment as usual (TAU) plus antidepressants.

Comparator: TAU or placebo or not applicable.

Study designs to be included: Original studies including randomized control trials (RCTs), observational studies and retrospective studies.

Eligibility criteria: All types of studies that examined the efficacy and safety of antidepressants added to treatment as usual (TAU) for patients with COVID-19 will be included.

Information sources: CNKI, WanFang, PsycINFO, Cochrane Library, PubMed, and EMBASE.

Main outcome(s): Clinical improvement/deterioration and all-cause mortality.